Cargando…

Can the onset of heart failure be delayed by treating diabetic cardiomyopathy?

The pathophysiology of diabetic cardiomyopathy (DC) is not fully understood. This frequently undiagnosed complication of chronic hyperglycemia leads to heart failure (HF). However, it is suggested that an appropriate metabolic control of diabetes at an early stage of this deleterious disease, is abl...

Descripción completa

Detalles Bibliográficos
Autores principales: Marcinkiewicz, Anna, Ostrowski, Stanisław, Drzewoski, Józef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5381046/
https://www.ncbi.nlm.nih.gov/pubmed/28396699
http://dx.doi.org/10.1186/s13098-017-0219-z
_version_ 1782519859414827008
author Marcinkiewicz, Anna
Ostrowski, Stanisław
Drzewoski, Józef
author_facet Marcinkiewicz, Anna
Ostrowski, Stanisław
Drzewoski, Józef
author_sort Marcinkiewicz, Anna
collection PubMed
description The pathophysiology of diabetic cardiomyopathy (DC) is not fully understood. This frequently undiagnosed complication of chronic hyperglycemia leads to heart failure (HF). However, it is suggested that an appropriate metabolic control of diabetes at an early stage of this deleterious disease, is able to inhibit the development and progression of DC to HF. Recently, it has been postulated that myocardial ischaemia plays an important role in the development of this pathology. Results of the antianginal pharmacological treatment and revascularization are unsatisfactory and reveal a gap in our knowledge and current approaches to treating DC. Most recent studies emphasize the ischaemic component of DC as a key target for therapeutic strategies, which could change its unfavorable history. More stress is put on an early diagnosis of coronary artery disease (CAD), promoting prompt revascularization. Choosing the accurate time of surgical revascularization, with the inclusion of the metabolic background, can ensure complete revascularization with better prognosis. This review will focus on the complexity of DC and summarize contemporary knowledge of treatment strategies for patients with diabetes and CAD.
format Online
Article
Text
id pubmed-5381046
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-53810462017-04-10 Can the onset of heart failure be delayed by treating diabetic cardiomyopathy? Marcinkiewicz, Anna Ostrowski, Stanisław Drzewoski, Józef Diabetol Metab Syndr Review The pathophysiology of diabetic cardiomyopathy (DC) is not fully understood. This frequently undiagnosed complication of chronic hyperglycemia leads to heart failure (HF). However, it is suggested that an appropriate metabolic control of diabetes at an early stage of this deleterious disease, is able to inhibit the development and progression of DC to HF. Recently, it has been postulated that myocardial ischaemia plays an important role in the development of this pathology. Results of the antianginal pharmacological treatment and revascularization are unsatisfactory and reveal a gap in our knowledge and current approaches to treating DC. Most recent studies emphasize the ischaemic component of DC as a key target for therapeutic strategies, which could change its unfavorable history. More stress is put on an early diagnosis of coronary artery disease (CAD), promoting prompt revascularization. Choosing the accurate time of surgical revascularization, with the inclusion of the metabolic background, can ensure complete revascularization with better prognosis. This review will focus on the complexity of DC and summarize contemporary knowledge of treatment strategies for patients with diabetes and CAD. BioMed Central 2017-04-04 /pmc/articles/PMC5381046/ /pubmed/28396699 http://dx.doi.org/10.1186/s13098-017-0219-z Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Marcinkiewicz, Anna
Ostrowski, Stanisław
Drzewoski, Józef
Can the onset of heart failure be delayed by treating diabetic cardiomyopathy?
title Can the onset of heart failure be delayed by treating diabetic cardiomyopathy?
title_full Can the onset of heart failure be delayed by treating diabetic cardiomyopathy?
title_fullStr Can the onset of heart failure be delayed by treating diabetic cardiomyopathy?
title_full_unstemmed Can the onset of heart failure be delayed by treating diabetic cardiomyopathy?
title_short Can the onset of heart failure be delayed by treating diabetic cardiomyopathy?
title_sort can the onset of heart failure be delayed by treating diabetic cardiomyopathy?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5381046/
https://www.ncbi.nlm.nih.gov/pubmed/28396699
http://dx.doi.org/10.1186/s13098-017-0219-z
work_keys_str_mv AT marcinkiewiczanna cantheonsetofheartfailurebedelayedbytreatingdiabeticcardiomyopathy
AT ostrowskistanisław cantheonsetofheartfailurebedelayedbytreatingdiabeticcardiomyopathy
AT drzewoskijozef cantheonsetofheartfailurebedelayedbytreatingdiabeticcardiomyopathy